Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease.
Majid O, Cao Y, Willis BA, Hayato S, Takenaka O, Lalovic B, Sreerama Reddy SH, Penner N, Reyderman L, Yasuda S, Hussein Z.
Majid O, et al.
CPT Pharmacometrics Syst Pharmacol. 2024 Dec;13(12):2111-2123. doi: 10.1002/psp4.13224. Epub 2024 Aug 29.
CPT Pharmacometrics Syst Pharmacol. 2024.
PMID: 39207112
Free PMC article.
Lecanemab (Leqembi) was recently approved by health authorities in the United States, Japan, and China to treat early Alzheimer's disease (AD), including patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease upon confirmation of amyloid …
Lecanemab (Leqembi) was recently approved by health authorities in the United States, Japan, and China to treat early Alzheimer's dis …